HANSOH PHARMA (03692): The application for marketing authorization of injectable HS-20093 for the treatment of small cell lung cancer has been accepted by the National Medical Products Administration.
Hansen Pharmaceutical (03692) announced that on September 2, 2026, the groups innovative drug, injectable HS-20093, has had its marketing authorization application accepted by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with small cell lung cancer (SCLC) who have failed prior platinum-based therapies. Injectable HS-20093 is an antibody-drug conjugate (ADC) targeting B7-H3 independently developed by the group.
HANSOH PHARMA (03692) announced that on September 2, 2026, the application for marketing authorization of the innovative drug HS-20093 for injection was accepted by the National Medical Products Administration (NMPA) of China. This drug is intended for the treatment of adult patients with small cell lung cancer (SCLC) who have previously failed platinum-based therapies. HS-20093 for injection is an antibody-drug conjugate (ADC) targeting B7-H3 independently developed by the group.
Related Articles
C FIN SERVICES (00605) spent HKD 47,540 to buy back 58,000 shares on September 2.
COSCO Shipping Holdings (601919.SH) has repurchased a total of 37.1575 million shares at a cost of 546 million yuan.
SC HOLDINGS (00413): The court has postponed the first hearing regarding the petition against Wah Shing Toys to September 16.
C FIN SERVICES (00605) spent HKD 47,540 to buy back 58,000 shares on September 2.
COSCO Shipping Holdings (601919.SH) has repurchased a total of 37.1575 million shares at a cost of 546 million yuan.
SC HOLDINGS (00413): The court has postponed the first hearing regarding the petition against Wah Shing Toys to September 16.
RECOMMEND
